NCT03597399: A Patient Registry Study for Patients Treated With Voretigene Neparvovec in US |
|
|
| Active, not recruiting | N/A | 87 | US | AAV2-hRPE65v2,voretigene neparvovec-rzyl, AAV2-hRPE65v2, voretigene neparvovec, gene therapy vector | Spark Therapeutics | Confirmed Biallelic RPE65 Mutation-associated Retinal Dystrophy | 06/25 | 06/25 | | |
NCT03602820: Long-term Follow-up Study in Subjects Who Received Voretigene Neparvovec-rzyl (AAV2-hRPE65v2) |
|
|
| Active, not recruiting | N/A | 41 | NA | AAV2-hRPE65v2, Voretigene Neparvovec-rzyl | Spark Therapeutics | Inherited Retinal Dystrophy Due to RPE65 Mutations | 03/30 | 06/30 | | |
